personalized medicine
Real-World Data Analysis Confirms Pan-Cancer Predictiveness of Foundation Medicine TMB Caller
Premium
The company worked with clinical investigators to analyze outcomes data across more than 8,000 treated individuals, reconfirming the validity of its FDA-approved TMB indication.
New York State DOH Approves Solvd Lab for Clinical PGx Testing
The company markets an assay intended to predict patients' risk of developing opioid use disorder, helping physicians tailor their use of these drugs.
Guardant Health, MiBA Partner to Pair Multi-Modal Analytics With Genomic Testing Data
The companies aim to promote broader, more consistent access to data-driven care and personalized, molecularly driven treatment.
Guardant Health, Cota Partner to Provide Clinicogenomic Cancer Data Resource for Biopharma
The companies believe that creating a unified set of clinical and genomic data will help biopharma clients accelerate their development of new targeted therapies.
Pathologists See Value Balance Shift Toward Comprehensive Sequencing for Hematologic Cancers
Premium
At the AMP annual meeting last week, speakers at multiple workshops said their field is reaching a tipping point as the clinical utility of NGS further solidifies.